{"record_type":"pith_number_record","schema_url":"https://pith.science/schemas/pith-number/v1.json","pith_number":"pith:2025:3Z74BQTJHSJA4Q4HCRRO2NHANV","short_pith_number":"pith:3Z74BQTJ","schema_version":"1.0","canonical_sha256":"de7fc0c2693c920e43871462ed34e06d6a7f14639b50a21a47728d4c51a947cb","source":{"kind":"arxiv","id":"2501.08410","version":1},"attestation_state":"computed","paper":{"title":"A Comparative Evaluation of Bayesian Model-Assisted Two-Stage Designs for Phase I/II Clinical Trials","license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","headline":"","cross_cats":[],"primary_cat":"stat.ME","authors_text":"Hao Sun, Jerry Li","submitted_at":"2025-01-14T19:57:18Z","abstract_excerpt":"The primary goal of a two-stage Phase I/II trial is to identify the optimal dose for the following large-scale Phase III trial. Recently, Phase I dose-finding designs have shifted from identifying the maximum tolerated dose (MTD) to the optimal biological dose (OBD). Typically, several doses are selected as recommended Phase II doses (RP2D) for further evaluation. In Phase II dose optimization trials, each RP2D is evaluated independently to determine its \"go/no-go\" decision. The optimal RP2D is then chosen from the remaining RP2Ds as the recommended Phase III dose (RP3D). The effectiveness of "},"verification_status":{"content_addressed":true,"pith_receipt":true,"author_attested":false,"weak_author_claims":0,"strong_author_claims":0,"externally_anchored":false,"storage_verified":false,"citation_signatures":0,"replication_records":0,"graph_snapshot":true,"references_resolved":false,"formal_links_present":false},"canonical_record":{"source":{"id":"2501.08410","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","primary_cat":"stat.ME","submitted_at":"2025-01-14T19:57:18Z","cross_cats_sorted":[],"title_canon_sha256":"4469ba84196312f8d154d8fc52e47f63df339231706fa14fdfc0936e3246f592","abstract_canon_sha256":"03a28dbddbc3a1c731ad3cb5f95cd64e5eecf4fa9d8c73191be667901dbec064"},"schema_version":"1.0"},"receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-07-05T10:01:02.289854Z","signature_b64":"IvdDruG+/4z3gI2lZbI8t3gQHM71CNoMfxGf6MwHVe1JHxxKZEp9a575oncpRHN8WxColf4mryyo5f+bjpraAg==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"de7fc0c2693c920e43871462ed34e06d6a7f14639b50a21a47728d4c51a947cb","last_reissued_at":"2026-07-05T10:01:02.289449Z","signature_status":"signed_v1","first_computed_at":"2026-07-05T10:01:02.289449Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"graph_snapshot":{"paper":{"title":"A Comparative Evaluation of Bayesian Model-Assisted Two-Stage Designs for Phase I/II Clinical Trials","license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","headline":"","cross_cats":[],"primary_cat":"stat.ME","authors_text":"Hao Sun, Jerry Li","submitted_at":"2025-01-14T19:57:18Z","abstract_excerpt":"The primary goal of a two-stage Phase I/II trial is to identify the optimal dose for the following large-scale Phase III trial. Recently, Phase I dose-finding designs have shifted from identifying the maximum tolerated dose (MTD) to the optimal biological dose (OBD). Typically, several doses are selected as recommended Phase II doses (RP2D) for further evaluation. In Phase II dose optimization trials, each RP2D is evaluated independently to determine its \"go/no-go\" decision. The optimal RP2D is then chosen from the remaining RP2Ds as the recommended Phase III dose (RP3D). The effectiveness of "},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2501.08410","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"integrity":{"clean":true,"summary":{"advisory":0,"critical":0,"by_detector":{},"informational":0},"endpoint":"/pith/2501.08410/integrity.json","findings":[],"available":true,"detectors_run":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938"},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"aliases":[{"alias_kind":"arxiv","alias_value":"2501.08410","created_at":"2026-07-05T10:01:02.289502+00:00"},{"alias_kind":"arxiv_version","alias_value":"2501.08410v1","created_at":"2026-07-05T10:01:02.289502+00:00"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2501.08410","created_at":"2026-07-05T10:01:02.289502+00:00"},{"alias_kind":"pith_short_12","alias_value":"3Z74BQTJHSJA","created_at":"2026-07-05T10:01:02.289502+00:00"},{"alias_kind":"pith_short_16","alias_value":"3Z74BQTJHSJA4Q4H","created_at":"2026-07-05T10:01:02.289502+00:00"},{"alias_kind":"pith_short_8","alias_value":"3Z74BQTJ","created_at":"2026-07-05T10:01:02.289502+00:00"}],"events":[],"event_summary":{},"paper_claims":[],"inbound_citations":{"count":0,"internal_anchor_count":0,"sample":[]},"formal_canon":{"evidence_count":0,"sample":[],"anchors":[]},"links":{"html":"https://pith.science/pith/3Z74BQTJHSJA4Q4HCRRO2NHANV","json":"https://pith.science/pith/3Z74BQTJHSJA4Q4HCRRO2NHANV.json","graph_json":"https://pith.science/api/pith-number/3Z74BQTJHSJA4Q4HCRRO2NHANV/graph.json","events_json":"https://pith.science/api/pith-number/3Z74BQTJHSJA4Q4HCRRO2NHANV/events.json","paper":"https://pith.science/paper/3Z74BQTJ"},"agent_actions":{"view_html":"https://pith.science/pith/3Z74BQTJHSJA4Q4HCRRO2NHANV","download_json":"https://pith.science/pith/3Z74BQTJHSJA4Q4HCRRO2NHANV.json","view_paper":"https://pith.science/paper/3Z74BQTJ","resolve_alias":"https://pith.science/api/pith-number/resolve?arxiv=2501.08410&json=true","fetch_graph":"https://pith.science/api/pith-number/3Z74BQTJHSJA4Q4HCRRO2NHANV/graph.json","fetch_events":"https://pith.science/api/pith-number/3Z74BQTJHSJA4Q4HCRRO2NHANV/events.json","actions":{"anchor_timestamp":"https://pith.science/pith/3Z74BQTJHSJA4Q4HCRRO2NHANV/action/timestamp_anchor","attest_storage":"https://pith.science/pith/3Z74BQTJHSJA4Q4HCRRO2NHANV/action/storage_attestation","attest_author":"https://pith.science/pith/3Z74BQTJHSJA4Q4HCRRO2NHANV/action/author_attestation","sign_citation":"https://pith.science/pith/3Z74BQTJHSJA4Q4HCRRO2NHANV/action/citation_signature","submit_replication":"https://pith.science/pith/3Z74BQTJHSJA4Q4HCRRO2NHANV/action/replication_record"}},"created_at":"2026-07-05T10:01:02.289502+00:00","updated_at":"2026-07-05T10:01:02.289502+00:00"}